List of insiders holdings for Apellis Pharmaceuticals Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| Morningside Venture Investments Ltd 10% Owner | 2022-02-14 16:05:11 | 12,806,342 0 | 12,806,342 | Form 13G |
| Potentia Holdings LLC 10% Owner | 2018-02-07 18:59:55 | 3,826,601 0 | 3,826,601 | Form 13G |
| Cormorant Asset Management LLC Cormorant Global Healthcare Master Fund LP CORMORANT PRIVATE HEALTHCARE FUND I LP Chen Bihua 10% Owner | 2020-02-14 16:07:26 | 2,700,000 0 | 2,700,000 | Form 13G |
| Cormorant Asset Management LLC Chen Bihua Cormorant Global Healthcare GP LLC Cormorant Global Healthcare Master Fund LP 10% Owner | 2020-02-14 16:07:26 | 2,700,000 0 | 2,700,000 | Form 13G |
| AJU IB Investment Co. Ltd. 10% Owner | 2017-11-13 16:29:47 | 0 2,292,062 | 2,292,062 | Form 4 |
| Hillhouse Capital Management Ltd. 10% Owner | 2019-02-14 15:15:04 | 2,098,581 0 | 2,098,581 | Form 13G |
| Francois Cedric Chief Executive Officer | 2024-11-01 18:43:29 | 313,662 1,721,568 | 2,035,230 | Form 4 |
| venBio Global Strategic Fund II L.P. 10% Owner | 2019-02-14 08:50:47 | 1,790,102 0 | 1,790,102 | Form 13G |
| Deschatelets Pascal Chief Scientific Officer | 2024-05-21 16:03:03 | 1,153,263 0 | 1,153,263 | Form 4 |
| GELLERT MICHAEL E 10% Owner | 2017-11-13 16:25:54 | 943,989 0 | 943,989 | Form 4 |
| Machiels Alec Director | 2024-01-02 16:08:19 | 376,509 411,950 | 788,459 | Form 4 |
| Axon Steven Chief Business Officer | 2018-11-15 20:40:03 | 398,499 0 | 398,499 | Form 4 |
| Dunlop A. Sinclair Director | 2024-09-24 16:20:24 | 152,126 100,000 | 252,126 | Form 4 |
| Watson David O. General Counsel | 2024-09-30 16:15:04 | 117,721 80,136 | 197,857 | Form 4 |
| Sullivan Timothy Eugene Chief Financial Officer | 2024-04-19 19:27:06 | 79,174 70,396 | 149,570 | Form 4 |
| SCHEIBLER LUKAS Chief Research Officer | 2023-12-05 19:40:46 | 107,690 0 | 107,690 | Form 4 |
| Baumal Caroline Chief Medical Officer | 2024-01-17 16:33:45 | 95,376 0 | 95,376 | Form 4 |
| Grossi Federico Chief Medical Officer | 2023-01-09 19:02:36 | 94,884 0 | 94,884 | Form 4 |
| Townsend Adam J. Chief Commercial Officer | 2024-02-13 17:05:03 | 92,453 0 | 92,453 | Form 4 |
| DeLong Mark Jeffrey Chief Business & Strat Officer | 2024-08-13 16:13:09 | 75,194 0 | 75,194 | Form 4 |
| Eisele Jeffrey Chief Development Officer | 2024-01-31 16:23:50 | 57,208 0 | 57,208 | Form 4 |
| Nicholson Nur Chief Technical Officer | 2024-03-14 16:17:21 | 56,287 0 | 56,287 | Form 4 |
| Lewis Karen Chief People Officer | 2024-01-31 16:28:12 | 46,387 0 | 46,387 | Form 4 |
| Chopas James George VP/Chief Accounting Officer | 2024-09-17 16:08:51 | 38,141 0 | 38,141 | Form 4 |
| Celona Lucia See Remarks | 2020-02-12 16:58:26 | 36,488 0 | 36,488 | Form 4 |
| Lackner Thomas A. See Remarks | 2020-02-12 16:50:35 | 24,075 0 | 24,075 | Form 4 |
| Brown Victoria L. Program Team Lead | 2023-01-24 16:57:32 | 23,556 0 | 23,556 | Form 4 |
| FONTEYNE PAUL R. Director | 2024-01-02 16:13:50 | 22,186 0 | 22,186 | Form 4 |
| Sadr Ahmad See Remarks | 2020-02-12 16:46:30 | 19,075 0 | 19,075 | Form 4 |
| O'Brien Stephanie Monaghan Director | 2024-01-02 16:12:29 | 17,186 0 | 17,186 | Form 4 |
| Chan Gerald Director | 2024-01-02 16:10:50 | 17,186 0 | 17,186 | Form 4 |
| Perry Nicole D Vice President - Accounting | 2021-08-03 16:23:59 | 11,008 0 | 11,008 | Form 4 |